Recent research highlights the effectiveness of galectin-3 inhibitors, like ProLectin-M and GB0139, in reducing COVID-19 severity by lowering viral load and improving symptoms [15], showcasing their potential in combating virus-induced inflammation and pneumonitis. The gene discussed is LGALS3; the disease is COVID-19.